Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development. 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

• Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018
• Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan
• Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns
• Key drivers and barriers that affect the market
• Coverage of pipeline molecules in various Phases of drug development
• Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma
• Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets

• Align your product portfolio to the markets with high growth potential
• Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth
• Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market
• Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

3.1 Introduction 10

3.1.1 Benign Tumor 10

3.1.2 Primary Liver Cancer 10

3.1.3 Secondary Liver Cancer 10

3.2 Symptoms 11

3.3 Diagnosis 11

3.3.1 Laboratory Tests 11

3.3.2 Imaging Tests 11

3.3.3 Others 12

3.4 Treatment Options 12

3.4.1 Surgery 13

3.4.2 Non-surgical 13

3.4.3 General Treatment Algorithm 15

3.4.4 Treatment by Stage 16

3.4.5 New Technologies in Treatment 18

4.1 Revenue 19

4.2 Annual Cost of Therapy 22

4.3 Marketed Products 23

4.3.1 Nexavar 23

4.3.2 Miripla 25

4.4 Treatment Usage Pattern 27

4.4.1 Prevalence Population 28

4.4.2 Diagnosed Population 28

4.4.3 Prescription Population 28

4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28

4.5.1 Drivers 28

4.5.2 Barriers 29

5.1 US 30

5.1.1 Introduction 30

5.1.2 Revenue 30

5.1.3 Cost of Therapy 32

5.1.4 Treatment Usage Pattern 33

5.2 Top Five European Countries 34

5.2.1 Introduction 34

5.2.2 Revenue 34

5.2.3 Cost of Therapy 36

5.2.4 Treatment Usage Pattern 37

5.3 Japan 38

5.3.1 Introduction 38

5.3.2 Revenue 38

5.3.3 Cost of Therapy 39

5.3.4 Treatment Usage Pattern 40

6.1 Introduction 41

6.2 R&D Product Pipeline by Stage of Development 43

6.2.1 Phase III 43

6.2.2 Phase II/III 44

6.2.3 Phase II 44

6.2.4 Phase I/II 45

6.2.5 Phase I 46

6.2.6 Pre-Clinical 47

6.2.7 Discovery 47

6.3 Profiles of Promising Molecules 48

6.3.1 PrevOnco 48

6.3.2 Ramucirumab 48

6.3.3 ThermoDox 49

6.3.4 Afinitor 50

7.1 Bayer 51

7.2 Dainippon Sumitomo Pharma 52

8.1 Introduction 53

8.2 Deals by Geography 54

8.3 Deals by Year 55

8.4 Mergers and Acquisition Deals 56

8.4.1 Overview 56

8.4.2 Profiles of Major M&A Deals 57

8.5 Licensing Agreements 58

8.5.1 Overview 58

8.5.2 Profiles of Major Licensing Agreements 60

8.6 Co-Development Agreements 62

8.6.1 Overview 62

8.6.2 Profiles of Major Co-Development Agreements 63

9.1 Market Definitions 64

9.2 Abbreviations 64

9.3 Bibliography 66

9.4 Research Methodology 67

9.4.1 Coverage 67

9.4.2 Secondary Research 68

9.4.3 Primary Research 68

9.5 Therapeutic Landscape 69

9.5.2 Market Size by Geography 70

9.6 Geographical Landscape 71

9.7 Pipeline Analysis 71

9.8 Competitive Landscape 72

9.8.1 Expert Panel Validation 72

9.9 Contact Us 72

9.10 Disclaimer 72

Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19

Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19

Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20

Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21

Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22

Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22

Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23

Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24

Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25

Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011 27

Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018 27

Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30

Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31

Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32

Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32

Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011 33

Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018 33

Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35

Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35

Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36

Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36

Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011 37

Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018 37

Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38

Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39

Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39

Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39

Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 40

Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 40

Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42

Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43

Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44

Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44

Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45

Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46

Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47

Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47

Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51

Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52

Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53

Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54

Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55

Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56

Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58

Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62

Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12

Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15

Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16

Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17

Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19

Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20

Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22

Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018 27

Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29

Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30

Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32

Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018 33

Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34

Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35

Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36

Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018 37

Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38

Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39

Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018 40

Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41

Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53

Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54

Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55

Figure 24: GBI Research Market Forecasting Model 71